Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The frequency of Cosentyx administration can vary depending on the specific condition being treated and the patient's response to the medication.

For adults with plaque psoriasis, Cosentyx is typically administered via subcutaneous injection once a week for the first five weeks, followed by maintenance doses every four weeks. In some cases, a healthcare provider may increase the dosing frequency to once every two weeks for the first four to twelve weeks, then once every four weeks thereafter.

For adults with psoriatic arthritis or ankylosing spondylitis, Cosentyx is usually administered via subcutaneous injection once a week for the first four weeks, followed by maintenance doses every four weeks.

It's important to note that the dosing regimen for Cosentyx may vary based on individual patient needs and responses to treatment. Therefore, it's crucial to follow the dosing schedule prescribed by a healthcare provider.

In summary, Cosentyx is typically administered via subcutaneous injection once a week for the first few weeks, followed by maintenance doses every four weeks for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the specific dosing regimen may vary based on individual patient needs and responses to treatment.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
2. Secukinumab. (2022). Drugs.com. <https://www.drugs.com/mtm/secukinumab.html>
3. Secukinumab (Cosentyx). (2022). DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/secukinumab>